This is a translation of the Swedish press release published 2022-09-27
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
The board of directors of Neola Medical AB (“Neola” or the “Company”) has, in connection with the rights issue of approximately SEK 55 million (the “Rights Issue”), which the board of directors resolved on 8 September 2022 and the extraordinary general meeting approved on 27 September 2022, prepared an EU-growth prospectus (the “Prospectus”). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on the Company’s website.
Read the entire translation of the Swedish press release here: Press communication